Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + Investigational Agents + Chemotherapy in 1L Gastroesophageal Adenocarcinoma
NCT06469944Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Sep 2024
- Primary completion
- Sep 2029
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 12
01
Overview
Phase 2, randomised, open-label trial of sacituzumab tirumotecan and patritumab deruxtecan in gastroesophageal adenocarcinoma (3 arms), sponsored by Merck & Co. Primary endpoints: Dose-Limiting Toxicities at 28 days, Adverse Events at 28 days and 2 more. Started Sep 2024; status: recruiting.
02
Drugs
sacituzumab tirumotecanpatritumab deruxtecan
03
Conditions
gastroesophageal adenocarcinoma
Beyond the preview
Go deeper on NCT06469944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06469944.